Evidence map›Paper›PMID 41923014›Full record

ArticleBMC cancer2026

Serum exosomal miR-192-5p as a novel predictive biomarker for immunochemotherapy response in advanced non-small cell lung cancer.

Yi-Fei Chen, Chu-Lin Zhang, Yuan Li, Chao-Feng Liu, Hui-Yu Jiang, Yong Yang, Hai-Long Wang, Min Pang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yi-Fei ChenDepartment of Pulmonary and Critical Care Medicine, the First Hospital; NHC Key Laboratory of Pneumoconiosis; Shanxi Key Laboratory of Chronic Respiratory Diseases and Pneumoconiosis, Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China.
Chu-Lin ZhangDepartment of Pulmonary and Critical Care Medicine, the First Hospital; NHC Key Laboratory of Pneumoconiosis; Shanxi Key Laboratory of Chronic Respiratory Diseases and Pneumoconiosis, Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China.
Yuan LiDepartment of Respiratory Medicine, Shanxi Province Cancer Hospital; Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital Affiliated to Shanxi Medical University, No. 3 Zhigong Xin Street, Taiyuan, Shanxi, 030013, China.
Chao-Feng LiuDepartment of Pulmonary and Critical Care Medicine, the First Hospital; NHC Key Laboratory of Pneumoconiosis; Shanxi Key Laboratory of Chronic Respiratory Diseases and Pneumoconiosis, Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China.
Hui-Yu JiangDepartment of Pulmonary and Critical Care Medicine, the First Hospital; NHC Key Laboratory of Pneumoconiosis; Shanxi Key Laboratory of Chronic Respiratory Diseases and Pneumoconiosis, Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China.
Yong YangSchool of Basic Medicine, Basic Medical Science Center, Shanxi Province Key Laboratory of Metabolic-Immune Homeostasis and Drug Innovation, Shanxi Medical University, No. 55 Wenhua Street, Jinzhong, Shanxi, 030600, China. yongyang811128@sxmu.edu.cn.
Hai-Long WangSchool of Basic Medicine, Basic Medical Science Center, Shanxi Province Key Laboratory of Metabolic-Immune Homeostasis and Drug Innovation, Shanxi Medical University, No. 55 Wenhua Street, Jinzhong, Shanxi, 030600, China. longwty@sxmu.edu.cn.
Min PangDepartment of Pulmonary and Critical Care Medicine, the First Hospital; NHC Key Laboratory of Pneumoconiosis; Shanxi Key Laboratory of Chronic Respiratory Diseases and Pneumoconiosis, Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan, Shanxi, 030001, China. pangminsdyy@sxmu.edu.cn.

Funding

the Central Guidance Fund for Local Science and Technology Development Projects YDZJSX2024D062the Science and Technology Cooperation and Exchange Special Project of Shanxi Province 202104041101012
6 · The paper itself

Abstract

backgroundImmunochemotherapy has become the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), yet response rates remain limited. Identifying reliable non-invasive biomarkers is crucial for predicting therapeutic benefit and enabling personalized treatment strategies.

methodsIn this prospective study, we enrolled 32 patients with unresectable locally advanced or metastatic NSCLC receiving tislelizumab combined with carboplatin and paclitaxel. Serum exosomes were isolated via ultracentrifugation before treatment initiation. Small RNA sequencing was performed to profile exosomal miRNA expression, with differential expression validated by quantitative RT-PCR. Patients were classified into clinical benefit (CB) and non-benefit (non-CB) groups based on RECIST 1.1 criteria after two treatment cycles.

resultsWe identified 19 differentially expressed exosomal miRNAs between CB and non-CB patients. Seven miRNAs were significantly upregulated in the CB group and validated by RT-qPCR. Among these, miR-192-5p demonstrated the highest predictive accuracy with an AUC of 0.77 (95% CI: 0.543–0.917). Functional enrichment analysis revealed that target genes of these miRNAs were involved in key signaling pathways including MAPK and Ras signaling, as well as biological processes related to apoptosis and cell cycle regulation.

conclusionThis study provides preliminary evidence that a panel of serum exosomal miRNAs, particularly miR-192-5p, may serve as non-invasive biomarkers associated with response to immunochemotherapy in advanced NSCLC. These hypothesis-generating findings warrant further validation in larger, independent cohorts to evaluate their potential utility in guiding treatment selection and patient stratification.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Non-Small-Cell LungExosomesLung NeoplasmsMicroRNAsAgedAntibodies, Monoclonal, HumanizedCarboplatinFemaleGene Expression Regulation, NeoplasticHumansImmunotherapyMaleMiddle AgedPaclitaxelAntibodies, Monoclonal, HumanizedBiomarkers, TumorCarboplatinMicroRNAsMIRN192 microRNA, humanPaclitaxelExosomal miRNAImmunochemotherapyLiquid biopsymiR-192-5pNon-small cell lung cancerPredictive biomarker

Identifiers

PMID41923014
PMCPMC13104417

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.